



L-02-0017
Study 1

Acute Dermal Toxicity Study in Rats
(970593); March 24, 1998



**ACUTE DERMAL TOXICITY
STUDY IN RATS**

RBM EXP. No. 970593

EEC Guidelines (B.3)
OECD Guidelines (402)

Issued on March 24, 1998

SPONSOR

AUSIMONT
Viale S. Pietro, 50/A
20021 BOLLATE (Milano)
Italy

PERFORMING LABORATORY

**Istituto di Ricerche Biomediche
"Antoine Marxer" RBM S.p.A.**
Via Ribes, 1
10010 - COLLERETTO GIACOSA (Torino)
Italy

TITLE OF THE STUDY

"Acute dermal toxicity study in rats treated with the test article [REDACTED]
[REDACTED]"

PURPOSE OF THE STUDY

The purpose of the study was to evaluate the acute dermal toxicity of the test article
[REDACTED]

INDEX

FOREWORD	4
QUALITY ASSURANCE STATEMENT	5
RBM MANAGEMENT DECLARATION OF GLP COMPLIANCE	6
SCIENTISTS INVOLVED IN THE STUDY	7
MATERIALS AND METHODS	8
RESULTS	15
SUMMARY AND CONCLUSIONS	18
GROUP DATA	20
TABLE 1. - Mortality and LD50 calculation	21
TABLE 2. - Clinical signs (maximum daily frequency)	22
TABLE 3. - Gross pathology examination	26
APPENDICES	31
APPENDIX 1. - Clinical signs incidence	32
APPENDIX 2. - Body weight	37
APPENDIX 3. - Gross pathology examination	41

This report consists of 48 pages.

Ivrea,

March 24, 1998



Dr. Ping Yu

RBM Study Director

FOREWORD

On behalf of **AUSIMONT - Viale S. Pietro, 50/A, 20021 BOLLATE Milano - Italy** - Istituto di Ricerche Biomediche "Antoine Marxer" RBM S.p.A., authorized by the Italian Health Authorities (1-2) to conduct safety studies, has performed an acute toxicity study by dermal route in Sprague Dawley Crl: CD(SD) BR rat (RBM-Experiment No. 970593), with the test article:



A sample of the substance used, along with pertinent documentation, is held in sufficient quantity in the RBM archives and is at the disposal of the Ministero della Sanità.

The undersigned declare that the experiment was conducted using the same batch of substance as that of the sample held on file.

For verification by the Ministero della Sanità, the undersigned moreover guarantee the identification and classification of all those materials, documents and recordings used in conducting the experiment, held on file for a period of at least 10 years from the date of this report. Following this time, they will be placed at the disposal of the Sponsor.

A handwritten signature in black ink, appearing to read 'Maraschin'.

Dr. Roberto Maraschin

Scientific Director Recognized by
the Italian Health Authorities as
Responsible for General Toxicology
Experimentation

A handwritten signature in black ink, appearing to read 'Conz'.

Dr. Angelo Conz

General Manager of the Istituto
di Ricerche Biomediche
"Antoine Marxer", RBM S.p.A.

Ivrea, March 24, 1998

- (1): **Pharmaceuticals:**
Authorization dated March 12, 1976 in accordance with "Circolare 73", May 16, 1974
- (2): **Chemicals:**
Authorization in accordance with DPR 927/81 (D.M. dated January 7, 1988 published in G.U. No. 12, dated January 16, 1988).

A solid black oval-shaped redaction mark.

144

QUALITY ASSURANCE STATEMENT

RBM Experiment number: 970593

Study title:

"Acute dermal toxicity study in rats treated with the test article
[REDACTED]"

Studies of the type described in this report are conducted in a manner which involves frequent repetition of identical or similar procedures.

In compliance with the Principles of Good Laboratory Practice, at the time of this study, procedure-based inspections were made by the Q.A.U. of critical phases and procedures relevant to this type of study. For the inspection of any given procedure, studies were selected at random. All such inspections were reported promptly to the study director and to facility management.

Dates of inspection/audit


January 13, 1998
March 20 - 23, 1998

Dates of report to
Study Director and Management

January 13, 1998
March 23, 1998

This report has been audited by the Q.A.U. and was found to be an accurate description of such methods and procedures as were used during the conduct of the study and an accurate reflection of the raw data.

Date of final report audit:

March 23, 1998

Enrico Invernizzi

Head of Quality Assurance Unit

Date :

March 23, 1998

 145

RBM MANAGEMENT DECLARATION OF GLP COMPLIANCE


Study No. 970593 entitled :

"Acute dermal toxicity study in rats treated with the test article [REDACTED]"

was performed in compliance with the OECD-GLP in the testing of chemicals, [C(81) 30 (final)], regulations also enforced by the Italian Health Authority [D.M. dated June 26, 1986 as published in G.U. No. 198, dated August 27, 1986 and D.L. January 27, 1992, No. 120 as published in G.U. (Supplement) No. 40, February 18, 1992].



Dr. Ping Yu
RBM Study Director



Dr. Angelo Conz
General Manager of the Istituto
di Ricerche Biomediche "Antoine
Marxer", RBM S.p.A.

Ivrea, March 27, 1998

145

SCIENTISTS INVOLVED IN THE STUDY

STUDY No. 970593

"Acute dermal toxicity study in rats treated with the test article

"

RBM Study Director

Dr. Ping Yu

Scientific Director Toxicology

Dr. Roberto Maraschin

Head of General Toxicology I Unit

Dr. Germano Oberto

REDACTED AS TO TRADE NAMES



RBM Exp. No. 970593

MATERIALS AND METHODS

1.48

EXPERIMENTAL DESIGN

RBM Experiment No.: 970593

Test article: [REDACTED]

Administration route: epidermal

Exposure period: about 24 hours

Duration of treatment period: single administration

Duration of post-treatment observation period: 14 days after the 24-hour exposure period

The test method was in accordance with European Economic Community Guidelines - Annex to Commission Directive 92/69/EEC of July 31, 1992 adapting to technical progress for the seventeenth time Council Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (B.3) and with Organization for Economic Cooperation and Development Guidelines (section 4, subpart 402, Paris 1981 and subsequent revisions).

TEST SYSTEM

Species, strain and substrain: Sprague Dawley Crl: CD (SD) BR rat

Justification for selection of the test system : the Sprague Dawley rat was chosen as rodent species since it is an appropriate experimental model widely accepted by Health Authorities, with documented susceptibility to a wide range of toxic substances

Dosages administered 2000 mg/kg in 5 males and 5 females
1000, 500 and 200 mg/kg in 5 males/dose

149

Body weight
(at randomization): Males: 230 - 304 g
Females: 221 - 261 g

Age (at randomization): no more than three months

Supplier: Charles River Italia S.p.A.
Via Indipendenza, 11
22050 CALCO (Lecco)
Shipping slips No.s 8504 (December 12, 1997), 8353
(December 5, 1997), 597 (January 23, 1998) and 793
(January 30, 1998)

Acclimatation: more than 5 days before the start of the test.
Animals were observed daily to ascertain their fitness for
the study.

Housing: 5 animals/sex/cage in air-conditioned room.
- Temperature: 22°C ± 2
- Relative humidity: 55% ± 10
- Air changes: about 20 / hour filtered on HEPA 99.97%
- Light: 12 hour cycle (7 a.m. - 7 p.m.)
- Cage size: grill cages 40.5x38.5x18h cm with stainless
steel feeder. The waste that dropped through the grill
bottom onto removable paper was periodically disposed of.

Animal identification: by appropriately coloring different areas of the limbs.
Cage card gave experiment number, dosage group, sex and
date of administration.

Diet: GLP 4RF21 top certificate pelleted diet produced by
Charles River Italia's feed licensee Mucedola S.r.l.,
Settimo Milanese. The declare contents, on the label, on
dry matter basis (moisture 12%), were:

crude protein	18.50%
crude fat	3.00%
crude fiber	6.00%
crude ash	7.00%

 150

The diet was supplemented by the Producer with vitamins and trace elements. The Producer supplies a certificate of analysis for nutrients and contaminants, the levels of which are within the limits proposed by EPA-TSCA (44FR:44053-44093, July 26, 1979).

RBM has the animal feed re-analyzed at least twice a year for bacterial contamination.

The diet was available "ad libitum" to the animals.

Water:

from the municipal water main system.

Water is filtered and distributed "ad libitum" to the animals by an automatic valve system.

Periodically drinking water is analyzed for microbial count, heavy metals, other contaminants (e.g. solvents, pesticides) and other chemical and physical characteristics. The accepted limits of quality of the drinking water were those defined in EEC directive 80/778

Contaminants that might interfere with the objectives of the study were not expected to be present in diet or drinking water.

TEST ARTICLE IDENTIFICATION, CHARACTERIZATION AND FORMULATE

The test article was supplied by the Sponsor as follows:

Identification:	[REDACTED]
Batch:	19387/20
Characteristics:	white solid
Purity:	>99%
Manufacturing date:	December, 1997
Expiry date:	December, 2000
Storage conditions:	at room temperature

TEST DESCRIPTION

Administration route:	epidermal
Reason for selection of administration route:	possible accidental exposure in humans

Experimental design:

Dose mg/kg		Treatment date	Final killing
2000	males:	January 15, 1998	found dead
2000	females*:	January 23, 1998	found dead
1000	males:	February 6, 1998	February 28, 1998
500	males	February 27, 1998	March 14, 1998
200	males	February 27, 1998	March 14, 1998

* 5 females were treated at the dose of 2000 mg/kg since there were no clinical signs observed in the males given the same dose during the first days of treatment.

Preparation of animals skin: approximately 24 hours before the test, fur was clipped from the dorsal and ventral area of the trunk of the test animals. Care was taken to avoid abrading the skin which could alter its permeability. An area of about 6x5 cm of the body dorsal surface was cleared for the application of the test article. This area corresponded to about 10% of the total body surface.

152

**Administration of the
test article:**

the test article was applied uniformly onto a porous gauze which was moistened with 0.9% NaCl.

The treated area was covered with the porous gauze dressing fixed to the skin with hypoallergenic non-irritating tape. The test site was further covered in a suitable manner in order to ensure that the animals could not ingest the test substance. At the end of the exposure period the residual test article was wiped off with water.

Observation period:

14 days (for the 500 and 200 mg/kg groups) or 22 days (for the 1000 mg/kg group) after the 24-hour exposure period. All animals of the 2000 mg/kg group died within 15 days of dosing.

**Observation of clinical signs
and mortality:**

at 30 minutes, 2, 4 and 6 hours on the first day after the administration (day 1) and then twice a day up to termination of the observation period.

Body weight:

twice pre-trial (at randomization and on day 1 just before administration) and on days 8, 15 and/or 22. Volume of administration was based on day 1 body weight.

Gross pathology:

on animals which died before the end of the study and on animals (fasted overnight) killed by excision of the femoral arteries, after i.p. overdosage anesthesia with 5% sodium pentobarbital, at the end of the observation period

Histology:

Histologic examination was not performed.

LD₅₀ and its statistical limits:

LD₅₀ was calculated by the method of the Probit (Bliss - Finney) - A.P. Rosiello et al., J. Tox. and Env. Health, 3: 797-809, 1977.

RECORD FILING

The protocol, a reserve sample of the test article used, the raw data bound in a register numbered 970593/1, the final report and all other documents pertinent to the conduct of this study, including records and reports of maintenance, cleaning, calibration and inspection of equipment, analysis of diet and water are filed at RBM premises for ten years from the issue date of this report and then sent to the Sponsor.

PROCEDURAL DETAILS

The study was conducted in accordance with the procedures described in the RBM Standard Operating Procedures (SOP's) collection.

Protection of animals used in the experiment is in accordance with Directive 86/609/EEC, enforced by the Italian D. L. No. 116 of January 27, 1992.

Physical facilities and equipment for accommodation and care of animals are in accordance with the provisions of EEC Council Directive 86/609.

The Institute is fully authorized by Competent Veterinary Health Authorities.

~~153~~ 154

REDACTED AS TO TRADE NAMES



RBM Exp. No. 970593

RESULTS

~~154~~ 155

CLINICAL OBSERVATIONS

MORTALITY (TABLE 1)

The deaths which occurred in the various dose groups are shown below:

Dose (mg/kg)	200	500	1000	2000
Treated animals	5 M	5M	5M	5M + 5F
Mortality	0	2M	4M	5M+5F
Total (%)	0%	40%	80%	100%

The deaths occurred within 18 days of treatment, with the first case observed on 7 days after dosing in one male of the 2000 mg/kg group.

The LD₅₀ was calculated to be 600 mg/kg with 95% confidence limits of 414 - 871 mg/kg.

CLINICAL SIGNS (TABLE 2 AND APPENDIX I)

Hypoactivity, piloerection, hunched posture, skin and mucosae pallor and hypothermia were observed in animals of the higher dose groups (500 - 2000 mg/kg), starting on days 6-7 after dosing at 2000 mg/kg and on days 8-15 after dosing at the lower doses. Some animals of the highest dose group (2000 mg/kg) also showed sedation and perineum stained with urine.

In addition, changes at the treatment site including skin edema and erythema were found in animals of the 2000 mg/kg group.

Recovery of the clinical changes in the surviving animals was achieved by day 13 (500 mg/kg group) or by day 21 (1000 mg/kg group) of the observation period.

No changes of note were seen in animals given the test article at the lowest dose (200 mg/kg).

156

BODY WEIGHT (*APPENDIX 2*)


Decrease in body weight was found in animals of the higher dose groups (2000 and 1000 mg/kg) during the study period. Body weights of animals in the lower dose groups were found to be unaffected by the test article administration.

POST-MORTEM EXAMINATION

GROSS PATHOLOGY (*TABLE 3 AND APPENDIX 3*)

At the autopsy of animals which died before the end of the observation period the macroscopic findings were liver paleness (2000 mg/kg group) or liver increased size (1000 and 500 mg/kg groups), congestion of stomach, decreased size and/or paleness of spleen and kidney medulla congestion. Moreover, skin edema (treatment site) was found in animals of the 2000 mg/kg group.

At the final killing increased size of liver was seen in animals of the 500 mg/kg group. No appreciable modifications were found in animals of the 200 mg/kg group.

 157

SUMMARY AND CONCLUSIONS

Experimental data from an acute toxicity study in which Sprague Dawley Crl:CD(SD) BR rats were treated by dermal route with the test article [REDACTED] are given in this report.

The test method was in accordance with European Economic Community Guidelines - Annex to Commission Directive 92/69/EEC of July 31, 1992 adapting to technical progress for the seventeenth time Council Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (B.3) and with Organization for Economic Cooperation and Development Guideline (section 4, subpart 402, Paris 1981 and subsequent revisions).

The test article was applied uniformly onto a porous gauze which was moistened with 0.9% NaCl and then, this porous gauze was fixed to the dorsal and ventral area of trunk of the rats (fur was clipped 24 hours previously). The individual dosages were based on body weight taken just before treatment.

The day of treatment was considered day 1 of the study. The animals were weighed twice before treatment (at randomization and on day 1 just before treatment) and on days 8, 15 and/or 22. They were clinically observed for 14 days (for the 200 and 500 mg/kg groups) or 22 days (for the 1000 mg/kg group; all 2000 mg/kg rats died within 15 days) after the 24-hour exposure period. Necropsy examination was performed on all animals which died before the end of the study. On day 16 or day 23 the surviving rats were killed (fasted overnight) by excision of the femoral arteries after i.p. overdosage anesthesia with 5% sodium pentobarbital and were submitted to a thorough autopsy.

The deaths which occurred in the various dose groups are shown below:

Dose (mg/kg)	200	500	1000	2000
Treated animals	5 M	5M	5M	5M + 5F
Mortality	0	2M	4M	5M+5F
Total (%)	0%	40%	80%	100%

The deaths occurred within 18 days of treatment, with the first case observed on 7 days after dosing in one male of the 2000 mg/kg group.

158

The LD₅₀ was calculated to be 600 mg/kg with 95% confidence limits of 414 - 871 mg/kg.

Hypoactivity, piloerection, hunched posture, skin and mucosae pallor and hypothermia were observed in animals of the higher dose groups (500 - 2000 mg/kg), starting on days 6-7 after dosing at 2000 mg/kg and on days 8-15 after dosing at the lower doses. Some animals of the highest dose group (2000mg/kg) also showed sedation and perineum stained with urine. In addition, local changes including skin edema and erythema (treatment site) were found in animals of the 2000 mg/kg group.

Recovery of the clinical changes in the surviving animals was achieved by day 13 (500 mg/kg group) or by day 21 (1000 mg/kg group).

No changes of note were seen in animals given the test article at the lowest dose (200 mg/kg).

Decrease in body weight was found in animals of the higher dose groups (2000 and 1000 mg/kg) during the study period. Body weights of animals in the lower dose groups were found to be unaffected by the test article administration.

At the necropsy of animals which died before the end of the observation period, the main macroscopic findings were liver paleness (2000 mg/kg group) or liver increased size (1000 and 500 mg/kg groups). Moreover, skin edema (treatment site) was found in animals of the 2000 mg/kg group.


At the final killing, increased size of liver was seen in animals of the 500 mg/kg group. No appreciable modifications were found in animals of the 200 mg/kg group.

In conclusion, the LD₅₀ of the test article [REDACTED], when administered by dermal route to the rats, was 600 mg/kg with 95% confidence limits of 414 - 871 mg/kg.

The compound induced delayed toxicity (liver was mainly involved) and local changes (treatment site) which were confined to the animals treated at the higher doses.

Dr. Ping Yu

RBM Study Director


March 24, 1998



Dr. Roberto Maraschin

Scientific Director Recognized by the
Italian Health Authorities as Responsible
for General Toxicology Experimentation

158

REDACTED AS TO TRADE NAMES



RBM Exp. No. 970593

GROUP DATA

~~157~~ 160

Test article: [REDACTED]
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

TABLE 1. - Mortality and LD50 calculation (p. 1)

Dose (mg/kg)	Males - Females			
	200	500	1000	2000
Treated animals	5	5	5	10
Day	7	0	0	1
8	0	0	0	1
9	0	0	0	1
10	0	0	0	1
12	0	0	0	1
13	0	2	0	1
14	0	0	0	2
15	0	0	1	2
18	0	0	3	0
Total no. (day 22)	0	2	4	10
Total (%)	.0%	40.0%	80.0%	100.0%

Median lethal dose (LD50) = 600.30
 95% confidence limits = 413.92 - 870.61
 Slope (SE) = 1.91 .51
 Heterogeneity P = .959 NS
 Linear regression Y = -7.1954 + 1.9063X

Test article: XXXXXXXXXX
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

TABLE 2. - Clinical signs (maximum daily frequency) (p. 1)
 (no. of animals affected, from-to)

Males

Dose (mg/kg)	200	500	1000	2000
no. of treated animals	5	5	5	5
Death	-	2 13d	4 15d-18d	5 7d-14d
Sedation	-	-	-	2 7d- 8d
Hypoactivity	-	2 11d-12d	5 8d-17d	3 6d-13d
Piloerection	-	2 11d-12d	5 8d-20d	3 6d-13d
Hunched posture	-	2 11d-12d	5 8d-20d	3 6d-13d
Skin and app. mucosae, pallor	-	2 12d-12d	4 15d-18d	2 6d-13d
Hypothermia	-	2 12d-12d	4 15d-17d	2 6d-13d
Skin treatment site: edema	-	-	-	5 2d-13d

- (not observed) from-to (first-last observation in one or more animals)
 Time : d (days)

162

Test article: XXXXXXXXXX
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

TABLE 2. - Clinical signs (maximum daily frequency) (p. 2)
 (no. of animals affected, from-to)

Males				
Dose (mg/kg)	200	500	1000	2000
no. of treated animals	5	5	5	5
.....
Skin treatment site: erythema	-	-	-	3 6d- 9d
Perineum stained with urine	-	-	-	1 6d- 6d
Recovery	-	3 13d	1 21d	-

- (not observed) from-to (first-last observation in one or more animals)
 Time : d (days)

163

Test article: [REDACTED]
Title : Acute dermal toxicity study in rats
RBM exp. : 970593

TABLE 2. - Clinical signs (maximum daily frequency) (p. 3)
(no. of animals affected, from-to)

Females

Dose (mg/kg)	2000
no. of treated animals	5
Death	5 8d-15d
Sedation	1 12d-12d
Hypoactivity	5 6d-14d
Piloerection	5 6d-14d
Hunched posture	5 6d-14d
Skin and app. mucosae, pallor	1 7d- 9d
Hypothermia	1 7d- 9d
Skin treatment site: edema	5 2d-13d

from-to (first-last observation in one or more animals)
Time : d (days)

164

Test article: [REDACTED]
Title : Acute dermal toxicity study in rats
RBM exp. : 970593

TABLE 2. - Clinical signs (maximum daily frequency)
(no. of animals affected, from-to) (p. 4)

Females

Dose (mg/kg)	2000
no. of treated animals	5
.....
Skin treatment site: erythema	1
	7d-10d
Perineum stained with urine	2
	6d-14d

from-to (first-last observation in one or more animals)
Time : d (days)

165

RBM Exp. No. 970593



26

Test article: [REDACTED]
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

TABLE 3. - Gross pathology examination (p. 1)
 (no. of cases, mean severity, %)

Dead or agonal sacrificed an.		Males			
Dose (mg/kg)		200	500	1000	2000
no. of animals		0	2	4	5
no. of animals without appreciable lesions		0	0	0	0
.....
General observation					
cannibalized		-	0	1	0
				25.00%	
Kidneys					
medulla, congestion		-	0	3 (2.3)	3 (2.0)
				75.00%	60.00%
Liver					
increased size		-	2 (2.5)	3 (2.3)	0
			100.00%	75.00%	
pale		-	0	0	5 (2.8)
					100.00%
Skin treatment area					
edema		-	0	0	4 (2.0)
					80.00%

- (not examined)
 Severity : 0 (very slight) 1 (slight) 2 (moderate) 3 (severe)

166

Test article: XXXXXXXXXX
 Title : Acute dermal toxicity study in rats
 REM exp. : 970593

TABLE 3. - Gross pathology examination (p. 2)
 (no. of cases, mean severity, %)

Dead or agonal sacrificed an.		Males			
Dose (mg/kg)		200	500	1000	2000
no. of animals		0	2	4	5
no. of animals without appreciable lesions		0	0	0	0
.....	
Spleen					
decreased size		-	0	3 (2.0) 75.00%	5 (2.0) 100.00%
Stomach					
congestion		-	0	2 (2.0) 50.00%	0

- (not examined)
 Severity : 0 (very slight) 1 (slight) 2 (moderate) 3 (severe)

167

Test article: XXXXXXXXXX
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

TABLE 3. - Gross pathology examination (p. 3)
 (no. of cases, mean severity, %)

Final killing		Males			
Dose (mg/kg)		200	500	1000	2000
no. of animals		5	3	1	0
no. of animals without appreciable lesions		5	0	0	0
.....	
Liver					
increased size		0	3 (2.0)	1 (2.0)	-
			100.00%	100.00%	

- (not examined)
 Severity : 0 (very slight) 1 (slight) 2 (moderate) 3 (severe)

168

Test article: [REDACTED]
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

TABLE 3. - Gross pathology examination (p. 4)
 (no. of cases, mean severity, %)

Dead or agonal sacrificed an. Females

Dose (mg/kg) 2000

no. of animals 5

no. of animals without appreciable lesions 0

Kidneys

medulla, congestion 3 (2.0)
 60.00%

Liver

pale 5 (2.6)
 100.00%

Skin treatment area

edema 2 (2.0)
 40.00%

Spleen

decreased size 3 (2.7)
 60.00%

Severity : 0 (very slight) 1 (slight) 2 (moderate) 3 (severe)

[REDACTED] 169

Test article: [REDACTED]
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

TABLE 3. - Gross pathology examination (p. 5)
 (no. of cases, mean severity, %)

Dead or agonal sacrificed an. Females

Dose (mg/kg) 2000

no. of animals 5

no. of animals without appreciable lesions 0

Stomach

congestion 1(2.0)
 20.00%

Severity : 0 (very slight) 1 (slight) 2 (moderate) 3 (severe)

[REDACTED] 170

REDACTED AS TO TRADE NAMES



RBM Exp. No. 970593

APPENDICES



171

Test article: XXXXXXXXXX
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

APPENDIX 1. - Clinical signs incidence (p. 1)
 (no. of animals affected)

Dose (mg/kg)	200															
Cage #	7M	Day 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Time	30m 2h 4h 6h	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A	M A M A M A M A M A M A M A M A M A
No clinical signs		5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5	5 5 5 5

Time: m (minutes) h (hours) M (morning) A (afternoon)

 172

Test article: [REDACTED]
Title : Acute dermal toxicity study in rats
RBM exp. : 970593

APPENDIX 1. - Clinical signs incidence (p. 2)
(no. of animals affected)

Dose (mg/kg)	500															
Cage #	5M	Day 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Time	30m	2h	4h	6h	M	A	M	A	M	A	M	A	M	A	M	A
Death																
No clinical signs	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
Hypoactivity																
Piloerection																
Hunched posture																
Skin and app. mucosae, pallor																
Hypothermia																

Time: m (minutes) h (hours) M (morning) A (afternoon)

173

Test article: XXXXXXXXXX
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

APPENDIX 1. - Clinical signs incidence (p. 3)
 (no. of animals affected)

Dose (mg/kg)	1000																	
Cage #	3M	Day 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
		Time 30m	2h	4h	6h	M	A	M	A	M	A	M	A	M	A	M	A	M
Death		5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
No clinical signs		5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
Hypoactivity																		
Piloerection																		
Hunched posture																		
Skin and app. mucosae, pallor																		
Hypothermia																		

Cage #	3M	Day 18	19	20	21	22
		Time	M	A	M	A
(follows)		Time	M	A	M	A
Death		3				
No clinical signs						
Piloerection						
Hunched posture						
Skin and app. mucosae, pallor						

Time: m (minutes) h (hours) M (morning) A (afternoon)

174

Test article: [REDACTED]
Title : Acute dermal toxicity study in rats
RBM exp. : 970593

APPENDIX 1. - Clinical signs incidence (p. 4)
(no. of animals affected)

[illegible]

Time: m (minutes) h (hours) M (morning) A (afternoon)

794

175

Test article: XXXXXXXXXX
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

APPENDIX 1. - Clinical signs incidence (p. 5)
 (no. of animals affected)

Dose (mg/kg)	2000															
Cage #	2F	Day 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
		Time 30m 2h 4h	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M	M A M A M A M A M A M A M A M A M
Death									1		1			1		2
No clinical signs		5	5	5	5											
Sedation													1	1		
Hypoactivity							1	1	5	4	4	3	3	2	2	2
Piloerection							2	2	5	4	4	3	3	3	2	2
Hunched posture							1	1	5	4	4	3	3	2	2	2
Skin and app. mucosae, pallor									1	1						
Hypothermia																
Skin treatment site: edema			5	5	5	5	5	2	2	2	2	2	2	2	2	2
Skin treatment site: erythema								1	1	1	1	1				
Perineum stained with urine							2	2	2	1	1	1	1	2	2	2

Time: m (minutes) h (hours) M (morning) A (afternoon)

175

176

Test article: [REDACTED]
Title : Acute dermal toxicity study in rats
RBM exp. : 970593

APPENDIX 2. - Body weight (g) (p. 1)
(individual)

Dose (mg/kg)		200				
		Animal #				
		31M	32M	33M	34M	35M
Week	day					
	0	230	230	230	230	230
1	1	235	231	232	230	231
2	8	295	291	298	290	286
3	15	349	329	320	326	315

176 177

Test article: [REDACTED]
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

APPENDIX 2. - Body weight (g) (p. 2)
 (individual)

Dose (mg/kg)		500				
		21M	22M	23M	24M	25M
Animal #	Week day					
0		236	232	230	232	234
1	1	241	236	234	237	238
2	8	278	253	269	255	254
3	15		278	294	269	

Test article: XXXXXXXXXX
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

APPENDIX 2. - Body weight (g) (p. 3)
 (individual)

Dose (mg/kg)		1000				
		Animal #	11M	12M	13M	14M 15M
Week	day					
	0		295	296	294	272 250
1	1		300	308	310	280 286
2	8		228	258	227	215 263
3	15		167	177	167	188
4	22					261

179

Test article: [REDACTED]
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

APPENDIX 2. - Body weight (g) (p. 4)
 (individual)

Dose (mg/kg)		2000									
		1M	2M	3M	4M	5M	6F	7F	8F	9F	10F
Animal #	Week day										
0		296	289	270	286	304	237	261	221	222	222
1	1	302	294	279	285	310	249	258	225	216	229
2	8	233	235	191	239		185		155	201	170

179 180

Test article: XXXXXXXXXX
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

APPENDIX 3. - Gross pathology examination (p. 1)
 (individual)

Dead or agonal sacrificed an.

Dose (mg/kg) 500

An#	Death	T I S U E	Gross observations
-----	day/code#	-----	-----
21M 13	M2	Liver	increased size, diffuse, severe
25M 13	M2	Liver	increased size, diffuse, moderate

Death code : M2 (Natural death)

180

181

Test article: XXXXXXXXXX
 Title : Acute dermal toxicity study in rats
 REM exp. : 970593

APPENDIX 3. - Gross pathology examination (p. 2)
 (individual)

Dead or agonal sacrificed an.

Dose (mg/kg) 1000

An#	Death day/code#	T I S S U E	Gross observations
11M 18	M2	Kidneys	medulla, congestion, diffuse, moderate
		Liver	increased size, diffuse, moderate
		Spleen	decreased size, diffuse, moderate
		Stomach	congestion, diffuse, moderate
12M 18	M2	Kidneys	medulla, congestion, diffuse, moderate
		Liver	increased size, diffuse, moderate
		Spleen	decreased size, diffuse, moderate
13M 18	M2	General observation	cannibalized
14M 15	M2	Kidneys	medulla, congestion, diffuse, severe
		Liver	increased size, diffuse, severe
		Spleen	decreased size, diffuse, moderate
		Stomach	congestion, diffuse, moderate

Death code : M2 (Natural death)

182

Test article: XXXXXXXXXX
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

APPENDIX 3. - Gross pathology examination (p. 3)
 (individual)

Dead or agonal sacrificed an.

Dose (mg/kg) 2000

An#	Death	T I S S U E	Gross observations
-----	day/code#	-----	-----
1M	14 M2	Liver	pale, diffuse, severe
		Skin treatment area	edema, diffuse, moderate
		Spleen	decreased size, diffuse, moderate
2M	12 M2	Kidneys	medulla, congestion, diffuse, moderate
		Liver	pale, diffuse, severe
		Skin treatment area	edema, diffuse, moderate
		Spleen	decreased size, diffuse, moderate
3M	9 M2	Kidneys	medulla, congestion, diffuse, moderate
		Liver	pale, diffuse, moderate
		Skin treatment area	edema, diffuse, moderate
		Spleen	decreased size, diffuse, moderate
4M	14 M2	Liver	pale, diffuse, severe
		Spleen	decreased size, diffuse, moderate

Death code : M2 (Natural death)

Test article: [REDACTED]
 Title : Acute dermal toxicity study in rats
 RBM exp. : 970593

APPENDIX 3. - Gross pathology examination (p. 4)
 (individual)

Dead or agonal sacrificed an.

Dose (mg/kg) 2000

An#	Death T I S U E	Gross observations
-----	day/code#-----	-----
5M 7	M2 Kidneys	medulla, congestion, diffuse, moderate
	Liver	pale, diffuse, severe
	Skin treatment area	edema, diffuse, moderate
	Spleen	decreased size, diffuse, moderate
6F 15	M2 Liver	pale, diffuse, moderate
	Spleen	decreased size, diffuse, severe
7F 8	M2 Kidneys	medulla, congestion, diffuse, moderate
	Liver	pale, diffuse, severe
	Skin treatment area	edema, diffuse, moderate
8F 10	M2 Kidneys	medulla, congestion, diffuse, moderate
	Liver	pale, diffuse, severe
	Skin treatment area	edema, diffuse, moderate
	Spleen	decreased size, diffuse, moderate

Death code : M2 (Natural death)

183 184

Test article: [REDACTED]
Title : Acute dermal toxicity study in rats
RBM exp. : 970593

APPENDIX 3. - Gross pathology examination (p. 5)
(individual)

Dead or agonal sacrificed an.

Dose (mg/kg) 2000

An#	Death	TI	S	U	E	Gross observations
-----	day/code#	-----	-----	-----	-----	-----
8F	10	M2	Stomach	congestion, diffuse, moderate
9F	13	M2	Liver	pale, diffuse, moderate
10F	15	M2	Kidneys	medulla, congestion, diffuse, moderate
			Liver	pale, diffuse, severe
			Spleen	decreased size, diffuse, severe

Death code : M2 (Natural death)

185

Test article: [REDACTED]
Title : Acute dermal toxicity study in rats
RBM exp. : 970593

APPENDIX 3. - Gross pathology examination (p. 6)
(individual)

Final killing

Dose (mg/kg) 200

An#	Death	T I S S U E	Gross observations
-----	day	-----	-----
31M	16	General observation	no macroscopically appreciable lesions
32M	16	General observation	no macroscopically appreciable lesions
33M	16	General observation	no macroscopically appreciable lesions
34M	16	General observation	no macroscopically appreciable lesions
35M	16	General observation	no macroscopically appreciable lesions

105 186

Test article: [REDACTED]
Title : Acute dermal toxicity study in rats
RBM exp. : 970593

APPENDIX 3. - Gross pathology examination (p. 7)
(individual)

Final killing

Dose (mg/kg) 500

An#	Death day	T I S S U E	Gross observations
22M	16	Liver	increased size, diffuse, moderate
23M	16	Liver	increased size, diffuse, moderate
24M	16	Liver	increased size, diffuse, moderate

186

187